Prognostic significance of 18F-FDG uptake in primary osteosarcoma after but not before chemotherapy: A possible association with autocrine motility factor/phosphoglucose isomerase expression

Clinical and Experimental Metastasis

Volumn 25, Issue 4, 2008, Pages 427-435

  Sato, Junko ^a   Yanagawa, Takashi ^a   Dobashi, Yoh ^b   Yamaji, Takehiko ^c   Takagishi, Kenji ^a   Watanabe, Hideomi ^c  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c GUNMA UNIVERSITY   (Japan)

Author keywords

Autocrine motility factor; Chemotherapy; FDG PET; Glycolysis; Hypoxia; Metastasis; Osteosarcoma; Phosphoglucose isomerase

Indexed keywords

ANTINEOPLASTIC AGENT; AUTOCRINE MOTILITY FACTOR; FLUORODEOXYGLUCOSE F 18; GLUCOSE 6 PHOSPHATE ISOMERASE; GLYCOLYTIC ENZYME; METHOTREXATE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADOLESCENT; ADULT; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; OSTEOSARCOMA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD;

ADOLESCENT; ADULT; AUTOCRINE MOTILITY FACTOR; BONE NEOPLASMS; CHILD; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE-6-PHOSPHATE ISOMERASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OSTEOSARCOMA; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS;

EID: 44449092446     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-008-9147-5     Document Type: Article

References (51)

1. Link MP, Goorin AM, Miser AW et al (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314:1600
2. Bruland OS, Pihl A (1997) On the current management of osteosarcoma: a critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 33:1725-1731
3. Davis AM, Bell RS, Goodwin PJ (1994) Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 12:423-431
4. Windhager R, Millesi H, Kotz R (1995) Resection-replatation for primary malignant tumours of the arm: an alternative to fore-quarter amputation. J Bone Joint Surg Br 77:176-184
5. Watanabe H, Ahmed AR, Shinozaki T et al (2003) Reconstruction with autologous pasteurized whole knee joint: part 2, application for osteosarcoma of the proximal tibia. J Orthop Sci 8:180-186
6. Bielack SS, Kempf-Bielack B, Delling G et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776-790
7. Lewis IJ, Nooij MA, Whelan J et al (2007) Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 99:112-128
8. Saeter G, Hoie J, Stenwig AE et al (1995) Systemic relapse of patients with osteogenic sarcoma: prognostic factors for long term survival. Cancer 75:1084-1093
9. Fletcher BD (1997) Imaging pediatric bone sarcomas: diagnosis and treatment-related issues. Radiol Clin North Am 35:1477-1494
10. Lawrence JA, Babyn PS, Chan HS et al (1993) Extremity osteosarcoma in childhood: prognostic value of radiologic imaging. Radiology 189:43-47
11. Rozental JM, Levine RL, Nicles RJ (1991) Changes in glucose uptake by malignant glicomas: preliminary study of prognostic significance. J Neurooncol 10:75-83
12. Kern KA, Brunetti A, Norton JA et al (1988) Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 29:181-186
13. Brenner W, Bohuslavizki KH, Eary JF et al (2003) PET imaging of osteosarcoma. J Nucl Med 44:930-942
14. Eary JF, O'Sullivan F, Powitan Y et al (2002) Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med 29:1149-1154
15. Adler LP, Blair HF, Makley JT et al (1991) Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 32:1508-1512
16. Nieweg OE, Pruim J, Van Genkel RJ et al (1996) Fluorine-18- fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 37:257-261
17. Watanabe H, Inoue T, Shinozaki T et al (2000) PET imaging of musculoskeletal tumors with F-18 alpha-methyltyrosine: comparison with F-18 fluorodeoxyglucose PET. Eur J Nucl Med 27:1509-1517
18. Griffeth LK, Dehdashti F, McGuire AH et al (1992) PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-d-glucose. Radiology 182:185-194
19. Suzuki H, Watanabe H, Shinozaki T et al (2004) PET imaging of musculoskeletal tumors in the shoulder girdle. J Shoulder Elbow Surg 13:635-647
20. Watanabe H, Shinozaki T, Yanagawa T et al (2000) Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG PET as an aid to preoperative planning. J Bone Joint Surg Br 82:760-767
21. Folpe AL, Lyles RH, Sprouse JT et al (2000) (F-18) fluorodeoxy-glucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 6:1279-1287
22. Messa C, Landone C, Pozzato C et al (2000) Is there a role for FDG PET in the diagnosis of musculoskeletal neoplasms [commentary]? J Nucl Med 41:1702-1703
23. Hawkins DS, Rajendran JG, Conrad EU III et al (2002) Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-d-glucose positron emission tomography. Cancer 94:3277-3284
24. Schulte M, Brecht-Krauss D, Werner M et al (1999) Evaluation of neoadjuvant chemotherapy response of osteogenic sarcoma using FDG-PET. J Nucl Med 40:1637-1643
25. 99mTc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med 43:1012-1017
26. Liotta LA, Mandler R, Murano G et al (1986) Tumor cell autocrine motility factor. Proc Natl Acad Sci USA 83:3302-3306
27. Watanabe H, Carmi P, Hogan V et al (1991) Purification of human tumor cell autocrine motility factor and molecular cloning of its receptor. J Biol Chem 266:13442-13448
28. Gurney ME, Apatoff BR, Spear GT et al (1986) Neuroleukin: a lymphokine product of lectin stimulated T cells. Science 234:574-581
29. Luo Y, Long JM, Lu C et al (2002) A link between maze learning and hippocampal expression of neuroleukin and its receptor gp78. J Neurochem 80:354-361
30. Xu W, Seiter K, Feldman E et al (1996) The differentiation and maturation mediator for human myeloid leukemia cells shares homology with neuroleukin or phosphoglucose isomerase. Blood 87:4502-4506
31. Zhi J, Sommerfeldt DW, Rubin CT et al (2001) Differential expression of neuroleukin in osseous tissues and its involvement in mineralization during osteoblast differentiation. J Bone Miner Res 16:1994-2004
32. Watababe H, Takehara K, Date M et al (1996) Tumor cell autocrine motility factor is neuroleukin/phosphohexose isomerase polypeptide. Cancer Res 56:2960-2963
33. Takanami I, Takeuchi K, Naruke M et al (1998) Autocrine motility factor in pulmonary adenocarcinomas: results of an immunohistochemical study. Tumour Biol 19:384-389
34. Dobashi Y, Watanabe H, Matsubara M et al (2006) Autocrine motility factor/glucose-6-phosphate isomerase is a possible predictor of metastasis in bone and soft tissue tumours. J Pathol 208:44-53
35. Dobashi Y, Watanabe H, Hirashima S et al (2006) Differential expression and pathological significance of autocrine motility factor/glucose-6-phosphate isomerase expression in human lung carcinomas. J Pathol 210:431-440
36. Enneking WF, Spanier SS, Goodman MA (1980) A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 153:106-120
37. Shinozaki T, Watanabe H, Yanagawa T et al (2002) Pirarubicin-based versus doxorubicin-based osteosarcoma chemotherapy. Ann Pharmacother 36:996-999
38. Shinozaki T, Watanabe H, Tomidokoro R et al (2000) Successful rescue by oral cholestyramine of a patient with methotrexate nephrotoxity: nonrenal excretion of serum methotrexate. Med Pediatr Oncol 34:226-228
39. Kawaguchi N, Matumoto S, Manabe J (1995) New method of evaluating the surgical margin and safety margin for musculoskeletal sarcoma, analyzed on the basis of 457 surgical cases. J Cancer Res Clin Oncol 121:555-563
40. Hawkins DS, Schuetze SM, Butrynski JE et al (2005) [18F] fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 23:8828-8834
41. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
42. Mantel M (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170
43. Franzius C, Daldrup-Link HE et al (2001) FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 12:479-486
44. Franzius C, Sciuk J, Brinkschmidt C et al (2000) Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med 25:874-881
45. Reske SN, Grillenberger KG, Glatting G et al (1997) Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med 38:1344-1348
46. Niizeki H, Kobayashi M, Horiuchi I, Hosokawa M, et al (2002) Hypoxia enhances the expression of autocrine motility factor and the motility of human pancreatic cancer cells. Br J Cancer 86:1914-1919
47. Yanagawa T, Watanabe H, Takeuchi T et al (2004) Overexpression of autocrine motility factor in metastatic tumor cells: possible association with augmented expression of KIF3A and GDI-beta. Lab Invest 84:513-522
48. Watanabe H, Kanbe K, Chigira M (1994) Differential purification of autocrine motility factors derived from a murine protein-free fibrosarcoma. Clin Exp Metastat 12:155-163
49. Schwartz MK (1976) Laboratory aids to diagnosis: enzymes. Cancer 37:542-548
50. Tsutsumi S, Hogan V, Nabi IR et al (2003) Overexpression of the autocrine motility factor/phosphoglucose isomerase induces transformation and survival of NIH-3T3 fibroblast. Cancer Res 63:242-249
51. Yanagawa T, Funasaka T, Tsutsumi S et al (2004) Novel roles of the autocrine motility factor/phophoglucose isomerase in tumor malignancy. Endocr Relat Cancer 11:749-759